JUL 23, 2020 7:36 AM PDT

Cancer Therapy Reduces Lung Scarring

WRITTEN BY: Tara Fernandez

Scientists at the Stanford Institute for Stem Cell Biology and Regenerative Medicine have discovered a striking parallel between scar tissue formation and tumor growth: they both evade immune surveillance. As a result of this similarity, therapies to reactivate the immune system to target cancer cells have been shown to also work for treating scar tissue in the lung. The work was published recently in Nature Communications.

Idiopathic lung fibrosis is caused by overactive scar tissue cells called fibroblasts. Though the precise triggers and accelerants of fibrosis progression are still not fully understood, what is known is that in general, lung scarring is bad news. Progression of the conditions greatly limits the patients’ ability to breathe normally, with devastating effects on their overall quality of life. The only clinical intervention for advanced-stage lung fibrosis is a lung transplant.

The study, led by pathology expert Gerlinde Wernig, MD, aimed to identify how the normal molecular pathways involved in preventing overactive fibroblasts are disrupted in the case of fibrosis. Why don’t circulating immune cells such as macrophages detect a problem?

“In idiopathic lung disease, these fibroblasts behave almost like cancer cells,” said Wernig. 

“They grow over normal lung structures, obliterating airways, and blocking the passage of air in and out of the blood.” Fascinatingly, this homology extends to how fibroblasts evade capture by the body’s immune cells — via the proteins CD47 and PD-1.

Another inflammatory molecule that came into play was IL-6, a molecule whose predominant role in cancer is to promote tumor growth.

“When we looked at clinical tissue samples from lung fibrosis patients, we saw a huge increase in IL-6,” Wernig said. “IL-6 is known to be associated with chronic inflammatory disease, but it wasn’t clear how the molecule was contributing to the scarring process.”

By experimentally blocking CD47 and IL6 in a mouse model of idiopathic lung fibrosis, Wernig and team saw a massive reduction in lung scarring, as a result of increased immune clearance of fibroblasts. According to Wernig, this is a breakthrough for lung fibrosis patients, for whom clinical interventions beyond oxygen ventilators are extremely limited.

“This study presents hope for a new treatment option that could improve the condition of patients with lung fibrosis.” 

 

 

Sources: Nature Communications, Stanford Medicine.


 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
AUG 24, 2020
Immunology
Injectable Drug Stops HIV From Entering Cells
AUG 24, 2020
Injectable Drug Stops HIV From Entering Cells
Once in the body, HIV tracks down T cells that bear the CD4 receptor. It attaches to these immune cells, fusing itself w ...
SEP 21, 2020
Immunology
The Perfect Storm: Wildfires, Flu and COVID-19
SEP 21, 2020
The Perfect Storm: Wildfires, Flu and COVID-19
Over 85 massive wildfires have swept through the West Coast, devastating communities in Washington, Oregon, and Californ ...
SEP 20, 2020
Microbiology
Middle-Aged Adults Might Always be Susceptible to H3N2 Flu
SEP 20, 2020
Middle-Aged Adults Might Always be Susceptible to H3N2 Flu
People born in the late 1960s or 1970s might be perpetually susceptible to the H3N2 influenza virus, according to new re ...
SEP 24, 2020
Immunology
Remember That Coronavirus You Once Met? Your T Cells Do.
SEP 24, 2020
Remember That Coronavirus You Once Met? Your T Cells Do.
The SARS-CoV-2 virus was first identified in December 2019 in Wuhan, Hubei, China and quickly escalated to a pandemic st ...
OCT 06, 2020
Immunology
COVID Triggers Abnormalities in Immune Monocytes
OCT 06, 2020
COVID Triggers Abnormalities in Immune Monocytes
University of Manchester immunologists are the first to make an interesting observation about the white blood cells of p ...
OCT 22, 2020
Cell & Molecular Biology
How a Gene Variant Raises the Risk of Multiple Sclerosis
OCT 22, 2020
How a Gene Variant Raises the Risk of Multiple Sclerosis
Now that sequencing the whole human genome is easier, faster, and cheaper than it used to be, scientists have been able ...
Loading Comments...